Ziploc. I agree. However, the point I was making is that, based on the link I provided, those REDUCEIT patents will likely be invalidated as obvious in the near future, if challenged, rendering any reversal in the Du decision moot. Generics could file ANDA’s anytime now IIRC. Reversing the Du decision is a long shot and would take at least a couple years? Even if AMRN were to challenge those ANDA filers and win, the insurers will still cover GV for CVD. IMO
I base my opinion on KM’s recent comments at JPM and Cowan regarding the US market. KM has stated several times that AMRN is focusing on EU and ROW because AMRN has lost IP in the US. To me, that means he realizes he can’t protect CVD IP from invalidation or stop payers from infringing and he won’t spend the money trying to do so. This is all based on my opinion and I defer to Marjac and North or other legal experts. I hope I’m wrong but basing my investing on that belief.
News 
Market Data 
Discover 
